Physician profile
Kenneth I Fields
NPI 1285659383
$11,155.09
in general payments reported to CMS, 2019-2025
44 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $475 · 2021: $605 · 2022: $1,609 · 2023: $1,929 · 2024: $2,685 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,051.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,069.00 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,412.71 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $1,296.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $547.93 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $539.10 | 2022-2025 | |
| Olympus America INC. | $361.86 | 2019-2025 | Endoclot Phs, Single Use Electrosurgical Knife Kd-655 |
| Boston Scientific Corporation | $342.39 | 2021-2025 | Overstitch Endoscopic Suturing System |
| Ironwood Pharmaceuticals, INC | $308.81 | 2019-2024 | Linzess |
| Lilly USA, LLC | $308.07 | 2024-2025 | Omvoh, Zepbound |
| Medtronic, INC. | $287.19 | 2021-2024 | Gi Genius |
| Intercept Pharmaceuticals, INC. | $264.13 | 2022-2025 | Ocaliva |
| Qol Medical, LLC | $252.73 | 2020-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $244.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $237.64 | 2022-2025 | Tremfya, Stelara |
| Celgene Corporation | $237.11 | 2022-2024 | Zeposia |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $235.34 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $193.93 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $185.49 | 2023-2025 | Ibsrela |
| Allergan, INC. | $178.80 | 2019 | |
| Amgen INC. | $177.56 | 2021-2025 | Uplizna, Amjevita, Avsola |
| Mallinckrodt Hospital Products INC. | $172.99 | 2024 | Terlivaz |
| Omega Medical Imaging, LLC | $170.91 | 2025 | |
| Phathom Pharmaceuticals, INC. | $135.63 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $134.52 | 2020-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.57 | 2023-2024 | Cyltezo, Jardiance |
| Aimmune Therapeutics, INC. | $126.51 | 2024-2025 | Vowst |
| Medtronic USA, INC. | $118.01 | 2020 | |
| Ferring Pharmaceuticals INC. | $49.35 | 2019-2023 | Rebyota |
| Shield Therapeutics INC | $48.24 | 2023 | Accrufer |
| Redhill Biopharma INC. | $36.59 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $36.43 | 2024-2025 | Iqirvo |
| Organon LLC | $35.87 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $33.70 | 2022 | |
| Enterra Medical, INC. | $33.14 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $31.29 | 2024 | Idacio |
| Celltrion USA INC. | $29.97 | 2025 | Vegzelma |
| Ucb, INC. | $28.56 | 2019 | |
| Evoke Pharma, INC. | $25.67 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.86 | 2022 | |
| Vivus LLC | $19.61 | 2025 | Qsymia |
| Novo Nordisk INC | $16.41 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $14.74 | 2023 | |
| Braintree Laboratories, INC. | $13.81 | 2024 | Suflave, Sutab |
| Dova Pharmaceuticals | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.